Article PDF first page preview

Article PDF first page preview

Background: Chronic kidney disease (CKD) elevates the risk of cardiovascular and overall mortality among maintenance hemodialysis (MHD) patients. Although initially designed to predict stroke in cases of atrial fibrillation, the CHA2DS2-VASc score demonstrates predictive utility, spanning several cardiovascular conditions. This study seeks to evaluate if the CHA2DS2-VASc score is effective in predicting cardiovascular and all-cause mortality for MHD patients. Methods: The data are part of the "Prospective Study of the Prognosis of Patients on Chronic Hemodialysis" (PROHEMO) developed in Salvador, BA, Brazil. We grouped patients according to CHA2DS2-VASc score ≤2 (group 1) and >2 (group 2). Cox regression was used to estimate the hazard ratio of death (HR): unadjusted; and adjusted for hemoglobin, creatinine, albumin, phosphorus, PTH, liver disease, neoplasia/cancer, months of hemodialysis. Additionally, the distribution of each variable in the CHA2DS2-VASc score and its association with mortality were evaluated. Based on the observed associations and the distribution of age (with only 1.3% of patients aged >75 years) and hypertension (only 4.6% normotensive, leading to an imprecise association estimate), a modified CHA2DS2-VASc score was created. Results: A total of 237 patients on hemodialysis (51.57 ± 12.46, 57% male) were included. Mean age was 51.6 ± 12.5 years. A total of 55 deaths, 21 from cardiovascular causes. Compared with CHA2DS2-VASc score <2, the unadjusted hazard of death (Model 1) for score ≥2 was twofold for all-cause mortality (HR=2.05; 95% CI: 1.20, 3.49) and more than three times higher for cardiovascular deaths (HR=3.53; 95% CI: 1.46, 8.54). These HRs did not change substantially with adjustment for covariates. In the most comprehensively adjusted Cox model, the HR for all-cause mortality was 2.43 (95% CI: 1.38, 4.23) and for cardiovascular mortality was 3.52 (95% CI: 1.40, 8.84). These results were similar to those observe for the modified version of CHA2DS2-VASc score.

Journal Section:
Clinical Practice
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial